We propose and demonstrate dendrimer-based coatings for a sensitive biochip surface that enhance the high-performance sorption of small molecules (i.e., biomolecules with low molecular weights) and the sensitivity of a label-free, real-time photonic crystal surface mode (PC SM) biosensor. Biomolecule sorption is detected by measuring changes in the parameters of optical modes on the surface of a photonic crystal (PC). We describe the step-by-step biochip fabrication process. Using oligonucleotides as small molecules and PC SM visualization in a microfluidic mode, we show that the PAMAM (poly-amidoamine)-modified chip’s sorption efficiency is almost 14 times higher than that of the planar aminosilane layer and 5 times higher than the 3D epoxy-dextran matrix. The results obtained demonstrate a promising direction for further development of the dendrimer-based PC SM sensor method as an advanced label-free microfluidic tool for detecting biomolecule interactions. Current label-free methods for small biomolecule detection, such as surface plasmon resonance (SPR), have a detection limit down to pM. In this work, we achieved for a PC SM biosensor a Limit of Quantitation of up to 70 fM, which is comparable with the best label-using methods without their inherent disadvantages, such as changes in molecular activity caused by labeling.
Psychotic and affective disorders, including schizophrenia (SCZ) and depression (MDD), affect millions of people globally. The overlapping symptoms of these diseases and the lack of objective diagnostic tools could lead to misdiagnosis. Recent studies suggest that the analysis of plasma lipid levels may help to develop new diagnostic tools. In this study, we investigated the plasma lipidome of psychiatric patients and healthy controls to identify disease-specific lipid species. Using untargeted mass spectrometry, we profiled blood plasma lipids from 416 patients with common psychotic and affective disorders and 272 healthy individuals from two different cohorts. We observed lipidome alterations in SCZ and MDD consistent with earlier findings. In total, 144 lipids showed significant changes, with 107 of them being concordant across both disorders, and 37 being discordant. Lipids that differentiated SCZ from MDD were mainly triacylglycerols with polyunsaturated fatty acid residues decreased in MDD. In an additional group of 111 patients with bipolar, schizotypal, and schizoaffective disorders, these lipid markers suggested a trend toward separating psychotic and affective disorders. Furthermore, a logistic regression model trained on lipid data distinguished SCZ from MDD with an ROC AUC of 0.83. Taken together, these results suggest that blood lipid profiling may aid in the objective differentiation of psychotic and affective disorders.